Sleep Europe 2026 | How will CSA guidelines evolve? New pharmacotherapies and advances in phrenic nerve stimulation

Winfried Randerath, MD, PhD, Bethanien Hospital, University of Cologne, Solingen, Germany, discusses how central sleep apnea (CSA) treatment and guidelines may evolve as new therapies emerge. Prof. Randerath highlights new pharmaceutical developments beyond carbonic anhydrase inhibitors, which have long been used in CSA, and expects drug therapy to become one aspect of treatment for both central and obstructive sleep apnea. He also highlights that phrenic nerve stimulation, already included in the guidelines, may become less expensive and more widely available as the technique improves. This interview took place at Sleep Europe 2026 in Maastricht, the Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.